學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Syntonix Pharmaceuticals
內容大綱
Syntonix Pharmaceuticals, a Boston biopharmaceutical startup company, was seeking additional financing for growth. The company had developed and patented an improved delivery platform for long-acting biopharmaceuticals and then utilized that technology to develop new therapies to treat chronic diseases. The Transceptor® technology utilized a unique biological pathway to allow efficient delivery of SynFusion™ drug therapies. Several companies licensed the technologies in joint development deals to address several different conditions: Hemophilia B, autoimmune disorders, and infertility, as well as for use in enhanced peptide inhalation. The company had used up Angel money and Rounds A and B of venture capital financing and was looking for an additional $80 - $100 million for growth. In September 2006, Syntonix was in negotiations with a VC syndicate to gain a 'C' Round of funding. One member of the proposed syndicate, Biogen Idec, indicated interest in buying Syntonix outright. The founders needed to make a decision about the offer.